Osteoporosis medication halts spinal disc mineralisation in zebrafish study

Genetic alteration of a collagen-IX gene in zebrafish led to progressive spinal disc hardening and vertebral fusion, reproducing features of human disc degeneration. The researchers observed that an initial breakdown of a supportive scaffold preceded mineral accumulation, and gene-expression profiling highlighted abnormalities in lipid processing, mTOR activity, phosphate regulation and vitamin A signalling. Administration of a bisphosphonate, a medication already prescribed for osteoporosis, blocked the abnormal mineralisation, and dietary restriction or anti-lipid drugs further reduced disc fusion.

These results point to phosphate handling and fat metabolism as promising avenues for future drug development. The work, funded by Arthritis UK and the BBSRC, was published in Communications Biology. Lead scientist Erika Kague described the discovery as a potential breakthrough for a condition that currently relies on surgery alone.